Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2023-07-28 3:46 pm Purchase |
2023-07-19 | 13D | Gossamer Bio, Inc. GOSS |
Growth Equity Opportunities 18 VGE LLC | 18,793,076 8.200% |
18,793,076![]() (New Position) |
Filing History |
2023-05-26 3:03 pm Purchase |
2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 15,742,792 9.990% |
3,605,999![]() (+29.71%) |
Filing History |
2022-12-19 5:31 pm Purchase |
2022-12-09 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 12,136,793 9.990% |
5,258,636![]() (+76.45%) |
Filing History |
2022-09-12 4:04 pm Purchase |
2022-09-01 | 13D | Celcuity Inc. CELC |
Growth Equity Opportunities 18 VGE LLC | 1,520,001 9.990% |
270,000![]() (+21.60%) |
Filing History |
2022-07-19 5:28 pm Purchase |
2022-07-06 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 6,878,157 9.900% |
6,878,157![]() (New Position) |
Filing History |
2022-05-24 5:10 pm Purchase |
2022-05-15 | 13D | Celcuity Inc. CELC |
Growth Equity Opportunities 18 VGE LLC | 1,250,001 8.400% |
1,250,001![]() (New Position) |
Filing History |